TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI® IQLIK™, a subcutaneous...
Hence then, the article about leqembi iqlik lecanemab irmb subcutaneous autoinjector named to time s best inventions of 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" )
Also on site :
- WWE RAW Results & Winners (October 13, 2025): The Vision backstab Seth Rollins; CM Punk wins triple-threat match; Asuka flatlines Rhea Ripley & more
- From Vision to Readiness: Vertiv Collaborates with NVIDIA to Advance 800 VDC Platform Designs to Power the Next Generation of AI Factories
- "SAL" and "SPL" Sign a Strategic Agreement to Enhance Air Mail Handling in The Kingdom